Business Wire

SynteractHCR Global Medical and Regulatory Affairs Expert Dr. Martine Dehlinger-Kremer Speaking at Nordic ePharma Day and Pediatric Drug Development Conferences in April

Del

Martine Dehlinger-Kremer, Ph.D., global vice president for medical and regulatory affairs at international contract research organization SynteractHCR, will speak on topics of special interest to the international biopharma community at two conferences this spring. At Nordic ePharma Day, to be held April 21, 2016, in Copenhagen, Dr. Dehlinger-Kremer will present “The New EU Clinical Trials Regulation: What Are the Changes and What Will the Impact Be on Clinical Research in the European Union.” At the Pediatric Drug Development Conference of the Medicines for Children Research Network Hungary in Budapest from April 27-28, she will address the status of pediatric regulations and their impact on drug development for children today.

An expert in working with global regulatory organizations, Dr. Dehlinger-Kremer has more than 29 years of experience in the clinical research industry and has spoken, in both the US and Europe, on the new EU Clinical Trials Regulation multiple times in the past two years since it was initially put forth by the European Commission. The Regulation’s goal is to harmonize trial procedures and make Europe a more attractive location for conducting clinical trials – but it is not just a European issue as it will impact some initial considerations for trials in the United States, too. Dr. Dehlinger-Kremer’s presentation will provide an overview of the CT Regulation from the regulatory point of view, an introduction to national pilot phases, and also will identify some of the challenges the Regulation might bring.

In her role as chair of the Paediatric Working Group for EUCROF (European CRO Federation), Dr. Dehlinger-Kremer will open the conference as keynote speaker at 9:00 a.m. on the first day with a discussion entitled, “The EU Regulatory Situation, Ten Years after Paediatric Regulation,” which addresses the status of drug development for children now. Her experience in this area, in addition to serving as the EUCROF Pediatric Working Group chair, includes being a member of the working group of Enpr-EMA, the European Network of Paediatric Research at the European Medicines Agency, as well as a member of the EFGCP Children Working Party. In addition, she has an impressive background in multiple levels of pediatric drug development and has worked closely with authorities to help improve clinical research in children.

“With her extensive global industry and regulatory experience, Martine’s knowledge and expertise has augmented the consultative capabilities we offer clients globally, to support them through all stages of their drug development needs,” said SynteractHCR CEO Wendel Barr. “She is tireless in her quest to improve the drug development process for adults and children alike, and we are very proud that she is a thought leader for not only our company but for the international community at large.”

Dr. Dehlinger-Kremer has contributed to the global development of numerous products, including orphan drugs and biosimilars, from early development stages through clinical studies and final registration. She has participated in more than 100 New Drug Applications (NDAs) and Marketing Authorization Applications (MAAs), in the maintenance of products on the market, and in numerous clinical studies across all phases. She has co-authored numerous papers for industry and scientific publications and has chaired and participated in regulatory sessions at the European Medicines Agency (EMA), Drug Information Association (DIA), Partnership in Clinical Trials, ePharma Day, New Paradigms, Bio2Device Group, International Quality & Productivity Center (IQPC), and more.

About SynteractHCR ( www.synteracthcr.com )

SynteractHCR is a full-service contract research organization with a successful two-decade track record supporting biotechnology, medical device, and pharmaceutical companies in all phases of clinical development. SynteractHCR has conducted Phase I-IV studies on six continents and 60 countries, offering expertise across multiple therapeutic areas, with notable depth in oncology, immunotherapy, CNS, infectious disease, endocrinology, cardiovascular and respiratory, among other indications. With its “Shared Work – Shared Vision” philosophy, SynteractHCR provides customized services collaboratively and cost effectively, ensuring on-time delivery of quality data to help bring tomorrow’s treatments to patients.

Contact information

For SynteractHCR
Beth Walsh, 760-230-2424
beth@clearpointagency.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Group Vivendi Africa Deploys Netcracker OSS to Enhance Service Management as it Expands Across the Continent12.12.2017 16:07Pressemelding

Netcracker Technology announced today that its OSS suite was selected and deployed to support the long-term growth strategy of Group Vivendi Africa (GVA). GVA is a newly formed affiliate of the French-based multinational conglomerate Vivendi with the goal to deploy and operate a fiber network across Africa. Netcracker's OSS will be used as a consolidated solution to identify service availability across GVA's operating countries and then fulfill and provision those services to customers. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171212005937/en/ Netcracker's highly productized, out-of-the-box applications enabled the OSS suite to be deployed in seven months, meeting GVA's demand to leverage an integrated service fulfillment and inventory solution that could satisfy its long-term growth expectations, as well as s

Philip Morris International Releases Latest Scientific Update for Smoke-Free Products on Clinical Program12.12.2017 15:23Pressemelding

Philip Morris International Inc. (PMI) (NYSE/Euronext Paris: PM) today released its latest Scientific Update for Smoke-Free Products, a regular publication on its research efforts to develop and assess a range of smoke-free alternatives to cigarettes. The latest issue of the Scientific Update can be found at this link. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171212005891/en/ Philip Morris International Releases Latest Scientific Update for Smoke-Free Products on Clinical Program (Photo: Business Wire) This issue of the Scientific Update provides a closer look at some of the principles and practices on which PMI’s scientific assessment program is built. Director Medical Affairs Dr. Patrick Picavet describes specific examples from PMI’s clinical program that highlight the company’s

Murex to Offer MX.3 Risk, Trading and Post-Trade Solutions on the AWS Cloud12.12.2017 14:00Pressemelding

Murex, an industry leader in trading, risk management and processing solutions for capital markets, announced they will run their MX.3 technology platform on Amazon Web Services, Inc. (AWS). With the acceleration of cloud adoption in capital markets, Murex and AWS agreed to collaborate to help clients migrate their Murex application workloads to the AWS Cloud. Murex clients are looking to consolidate more and more of their capital markets activity on the MX.3 platform and this means their need for infrastructure is increasing. New regulatory requirements are also driving financial organizations to use cloud to scale up their computing capacity. Murex is collaborating with AWS to meet the demand from clients to support deployment of the Murex offering on the AWS Cloud. Murex is working on the validation of a range of deployment scenarios, from using AWS Cloud for bursting grid

Darzalex®▼(daratumumab) Combination Regimen Significantly Improved Outcomes for Newly Diagnosed Multiple Myeloma Patients who are Transplant Ineligible12.12.2017 13:33Pressemelding

Janssen-Cilag International NV (“Janssen”) today announced data from the Phase 3 ALCYONE study, showing Darzalex® (daratumumab) in combination with bortezomib, melphalan and prednisone (VMP) significantly improved clinical outcomes, including reducing the risk of disease progression or death by 50 percent, in patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation (ASCT).1 These data were accepted as a late-breaking abstract (LBA) for presentation at the 59th American Society of Hematology (ASH) Annual Meeting in Atlanta, today at 7:30 a.m. ET (Abstract #LBA-4).1 Study findings were simultaneously published in the New England Journal of Medicine (NEJM) . 2 Daratumumab is currently indicated for use in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for

CTS Engines Announces Senior Management Hire12.12.2017 13:00Pressemelding

CTS Engines, the global leader for mature jet engine maintenance, announced today that it had hired Diane E. Cavuoto as Senior Vice President, Supply Chain, in an effort to continue to provide its customers with outstanding engine overhaul services. Ms. Cavuoto will be based in CTS’s Ft. Lauderdale headquarters and will report directly to Vesa Paukkeri, CTS’s President and Chief Operating Officer. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171212005050/en/ Diane E. Cavuoto, Senior Vice President, Supply Chain, for CTS Engines (Photo: Business Wire) Ms. Cavuoto, most recently Vice President, Strategic Sourcing at Honeywell International, brings years of supply chain management experience to CTS. In her prior role at Honeywell, Ms. Cavuoto managed a global commodity team of 150 employees managing $4

MIPI Alliance Opens Access to its MIPI I3C Sensor Interface Specification12.12.2017 13:00Pressemelding

The MIPI® Alliance, an international organization that develops interface specifications for mobile and mobile-influenced industries, today announced it is opening access to its sensor interface specification, MIPI I3C. Starting today, all companies, including those not currently members of MIPI Alliance, may access the MIPI I3C v1.0 specification so they may evaluate the incorporation of the specification into their sensor integration plans and design applications. “MIPI I3C provides a welcome update to the I2C technology that has been widely adopted over the past 35 years. Extending access provides an opportunity to spur innovation and help other industries beyond mobile," said Joel Huloux, chairman of MIPI Alliance. "It helps MIPI members as well, because it supports greater adoption and interoperability, strengthens the ecosystem and provides for a richer

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom